Claims for Patent: 9,090,876

Summary for Patent: 9,090,876

Title:	Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
Abstract:	The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects.
Inventor(s):	Velardi; Andrea (Perugia, IT), Romagne; Francois (La Ciotat, FR)
Assignee:	INNATE PHARMA S.A. (Marseilles, FR)
Application Number:	12/847,090
Patent Claims:	1. A pharmaceutical composition comprising: (a) a therapeutically effective amount of a therapeutic antibody or antigen-binding fragment that specifically binds to an antigen that is expressed on target cells but not on NK cells, wherein the therapeutic antibody or antigen-binding fragment binds to CD16 via its Fc region and is capable of mediating depletion of the target cells by antibody-dependent cell-mediated cytotoxicity (ADCC); (b) at least one NK cell-potentiating compound that specifically binds to and blocks an inhibitory receptor expressed on the surface of an NK cell; and (c) a pharmaceutically acceptable carrier, wherein the at least one NK cell-potentiating compound is present in an amount sufficient to enhance the efficacy of the therapeutic antibody or antigen-binding fragment by enhancing the depletion of the target cells by ADCC. 2. The composition of claim 1, wherein the therapeutic antibody or antigen-binding fragment comprises a human or non-human primate IgG1 or IgG3 Fc portion. 3. The composition of claim 1, wherein the at least one NK cell-potentiating compound comprises an antibody or an antigen binding fragment thereof. 4. The composition of claim 1, wherein the at least one NK cell-potentiating compound comprises a monoclonal antibody or comprises an antigen binding fragment thereof. 5. The composition of claim 1, wherein the at least one NK cell-potentiating compound comprises a human, humanized or chimeric antibody or comprises an antigen binding fragment thereof. 6. The composition of claim 1, wherein the therapeutic antibody is a monoclonal antibody or comprises an antigen binding fragment thereof. 7. The composition of claim 6, wherein the monoclonal antibody is a human, humanized or chimeric antibody or comprises an antigen binding fragment thereof. 8. The composition of claim 6, wherein the therapeutic antibody or antigen-binding fragment is not conjugated with a radioactive or toxic moiety. 9. The composition of claim 1, wherein the therapeutic antibody is rituximab or alemtuzumab. 10. The composition of claim 3, wherein the at least one NK cell-potentiating compound is an antibody or antigen binding fragment thereof that binds to and blocks an inhibitory receptor expressed on the surface of an NK cell selected from the group consisting of KIR2DL1, KIR2DL2/3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, NKG2A, NKG2C NKG2E and LILRB5. 11. The composition of claim 1, wherein the at least one NK cell-potentiating compound binds to a common determinant of KIR2DL human receptors and inhibits KIR2DL-mediated inhibition of NK cell cytotoxicity. 12. The composition of claim 11, wherein the at least one NK cell-potentiating compound binds to a common determinant of KIR2DL1, KIR2DL2, and KIR2DL3 human receptors and inhibits KIR2DL1-, KIR2DL2-, and KIR2DL3-mediated inhibition of NK cell cytotoxicity. 13. The composition of claim 12, wherein the at least one NK cell-potentiating compound inhibits the binding of an HLA-C polypeptide having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of an HLA-C polypeptide having an Asn residue at position 80 to human KIR2DL2 and KIR2DL3 receptors. 14. The composition of claim 1, wherein the at least one NK cell-potentiating compound binds to the same epitope as monoclonal antibody DF200 produced by hybridoma DF200 (deposited as CNCM 1-3224), or monoclonal antibody EB6. 15. The composition of claim 1, wherein the at least one NK cell-potentiating compound competes with monoclonal antibody DF200 produced by hybridoma DF200 (deposited as CNCM 1-3224), or monoclonal antibody EB6, for binding to a KIR receptor expressed on the surface of a human NK cell. 16. The composition of claim 1, wherein the at least one NK cell-potentiating compound comprises monoclonal antibody DF200 produced by hybridoma DF200 (deposited as CNCM 1-3224) or a fragment or derivative thereof, or monoclonal antibody EB6 or a fragment or derivative thereof. 17. A kit comprising: (a) a therapeutically effective amount of a therapeutic antibody or antigen-binding fragment that specifically binds an antigen that is expressed on target cells but not on NK cells, wherein the therapeutic antibody or antigen-binding fragment binds to CD 16 via its Fc region and is capable of mediating depletion of the target cells by antibody-dependent cell-mediated cytotoxicity (ADCC); and (b) at least one NK cell-potentiating compound that specifically binds to and blocks an inhibitory receptor expressed on the surface of an NK cell, wherein the at least one NK cell-potentiating compound when co-administered with the therapeutic antibody or antigen-binding fragment enhances the efficacy of the therapeutic antibody or antigen-binding fragment by enhancing the depletion of the target cells by ADCC. 18. The kit of claim 17, wherein moieties (a) and (b) are suitable for co-administration to a subject in need of depletion of said target cells. 19. The kit of claim 17, which further includes instructions how to use moieties (a) and (b). 20. The kit of claim 17, wherein said therapeutic antibody or antigen binding fragment comprises a human or non-human primate IgG1 or IgG3 Fc portion. 21. The kit of claim 17, wherein the at least one NK cell-potentiating compound is an antibody or comprises an antigen binding fragment thereof. 22. The kit of claim 17, wherein the at least one NK cell-potentiating compound is a monoclonal antibody or comprises an antigen binding fragment thereof. 23. The kit of claim 22, wherein the at least one NK cell-potentiating compound comprises a human, humanized or chimeric antibody or comprises an antigen binding fragment thereof. 24. The kit of claim 17, wherein the therapeutic antibody is a monoclonal antibody or comprises an antigen binding fragment thereof. 25. The kit of claim 24, wherein the monoclonal antibody is a human, humanized or chimeric antibody or comprises an antigen binding fragment thereof. 26. The kit of claim 24, wherein the therapeutic antibody or antigen binding fragment is not conjugated with a radioactive or toxic moiety. 27. The kit of claim 17, wherein the therapeutic antibody is rituximab or alemtuzumab. 28. The kit of claim 21, wherein the at least one NK cell potentiating compound is an antibody or antigen binding fragment thereof that specifically binds to and blocks an inhibitory receptor expressed on the surface of an NK cell selected from the group consisting of KIR2DL1, KIR2DL2/3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, NKG2A, NKG2C NKG2E and LILRB5. 29. The kit of claim 17, wherein the at least one NK cell-potentiating compound binds to a common determinant of KIR2DL human receptors and inhibits KIR2DL-mediated inhibition of NK cell cytotoxicity. 30. The kit of claim 29, wherein the at least one NK cell-potentiating compound binds to a common determinant of KIR2DL1, KIR2DL2, and KIR2DL3 human receptors and inhibits KIR2DL1-, KIR2DL2-, and KIR2DL3-mediated inhibition of NK cell cytotoxicity. 31. The kit of claim 30, wherein the at least one NK cell-potentiating compound inhibits the binding of a HLA-C polypeptide having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C polypeptide having an Asn residue at position 80 to human KIR2DL2 and KIR2DL3 receptors. 32. The kit of claim 17, wherein the at least one NK cell-potentiating compound binds to the same epitope as monoclonal antibody DF200 produced by hybridoma DF200 (deposited as CNCM I-3224), or monoclonal antibody EB6. 33. The kit of claim 17, wherein the at least one NK cell-potentiating compound competes with monoclonal antibody DF200 produced by hybridoma DF200 (deposited as CNCM I-3224), or monoclonal antibody EB6, for binding to a KIR receptor at expressed on the surface of a human NK cell. 34. The kit of claim 17, wherein the at least one NK cell-potentiating compound comprises a monoclonal antibody DF200 produced by hybridoma DF200 (deposited as CNCM I-3224) or a fragment or derivative thereof, or monoclonal antibody EB6 or a fragment or derivative thereof. 35. The composition of claim 1, wherein the therapeutic antibody or antigen-binding fragment specifically binds to an antigen expressed on cells selected from tumor cells, virus-infected cells, allogeneic cells, non-tumorigenic pathological cells, pathological immunocompetent cells, and endothelial cells. 36. The composition of claim 1, wherein the at least one NK cell-potentiating compound enhances the ability of the therapeutic antibody to deplete said target cells by at least 30%. 37. The composition of claim 1, wherein said NK cell-potentiating compound enhances the ability of said therapeutic antibody to deplete said target cells by at least 50%. 38. The composition of claim 1, wherein the therapeutic antibody or antigen-binding fragment elicits essentially no ADCC in the absence of the at least one NK cell-potentiating compound. 39. The kit of claim 17, wherein the at least one NK cell-potentiating compound enhances the ability of the therapeutic antibody to deplete said target cells by at least 30%. 40. The kit of claim 17, wherein the at least one NK cell-potentiating compound enhances the ability of the therapeutic antibody to deplete said target cells by at least 50%. 41. The kit of claim 17, wherein said therapeutic antibody or antigen binding fragment elicits essentially no ADCC in the absence of said at least one NK cell-potentiating compound. 42. The composition of claim 1, wherein the therapeutic antibody or antigen-binding fragment thereof binds an antigen selected from CD20, CD52, CD33, HLA-DR, CD22, HER2, erbB2, CA125, MUC1, PEM antigen, CD44, gp72, EpCAM, VEGFR, CD18, nuC242 EGFR, HER-1, CEA, .alpha.V.beta.3, KDR (VEGFR2), VRS, CMV, HBs, CD25, TNF-.alpha., CD80, IgE, CD11a (LFA-1), CD4, CD3, CD64, CD147, .alpha.4 .beta.1-.alpha.4 .beta.7, integrin .beta.7, .alpha.4 .beta.7, HLA-DR10 .beta., GD2, SK-1, IL-8, VLA-4, CD40L, E-selectin, CD11/CD18, ICAM-3, CBL, CD147, CD23, T1-ACY, TTs, CA19.9, PSA, HMFG1, hCH, collagen, CD46, 17A-1, HM1.24, CD38, IL-15R, I1-6, TRAIL-R1, VEGF2, BlyS, SCLS, Lewis Y antigen, VE cadherin, CD56, mertansine/mucine, AFP, CSap, CD30, PSMA, Cd15, CD19/CD3, mesothelin, DNA, histone, a5B1 integrin, p97, and CD5. 43. The kit of claim 17, wherein the therapeutic antibody or antigen-binding fragment thereof binds an antigen selected from CD20, CD52, CD33, HLA-DR, CD22, HER2, erbB2, CA125, MUC1, PEM antigen, CD44, gp72, EpCAM, VEGFR, CD18, nuC242 EGFR, HER-1, CEA, .alpha.V.beta.3, KDR (VEGFR2), VRS, CMV, HBs, CD25, TNF-.alpha., CD80, IgE, CD11a (LFA-1), CD4, CD3, CD64, CD147, .alpha.4 .beta.1-.alpha.4 .beta.7, integrin .beta.7, .alpha.4 .beta.7, HLA-DR10 .beta., GD2, SK-1, IL-8, VLA-4, CD40L, E-selectin, CD11/CD18, ICAM-3, CBL, CD147, CD23, T1-ACY, TTs, CA19.9, PSA, HMFG1, hCH, collagen, CD46, 17A-1, HM1.24, CD38, IL-15R, I1-6, TRAIL-R1, VEGF2, BlyS, SCLS, Lewis Y antigen, VE cadherin, CD56, mertansine/mucine, AFP, CSap, CD30, PSMA, Cd15, CD19/CD3, mesothelin, DNA, histone, a5B1 integrin, p97, and CD5. 44. The composition of claim 1, wherein the target cells are tumor cells or virus-infected cells. 45. The composition of claim 35, wherein the pathological immunocompetent cells are B lymphocytes, T lymphocytes, or antigen-presenting cells. 46. The composition of claim 35, wherein the healthy cells are endothelial cells to be targeted in an anti-angiogenic therapeutic strategy. 47. The kit of claim 17, wherein the therapeutic antibody or antigen-binding fragment specifically binds to an antigen expressed on cells selected from tumor cells, virus-infected cells, allogeneic cells, non-tumorigenic pathological cells, pathological immunocompetent cells, and endothelial cells. 48. The kit of claim 17, wherein the target cells are tumor cells or virus-infected cells. 49. The kit of claim 47, wherein the pathological immunocompetent cells are B lymphocytes, T lymphocytes, or antigen-presenting cells. 50. The kit of claim 47, wherein the healthy cells are endothelial cells to be targeted in an anti-angiogenic therapeutic strategy. 51. The composition of claim 1, wherein the at least one NK cell-potentiating compound is an antibody or antigen-binding fragment thereof that binds to a common determinant of KIR2DL human receptors and inhibits KIR2DL -mediated inhibition of NK cell cytotoxicity. 52. The kit of claim 17, wherein the at least one NK cell-potentiating compound is an antibody or antigen-binding fragment thereof that binds to a common determinant of KIR2DL human receptors and inhibits KIR2DL-mediated inhibition of NK cell cytotoxicity. 53. The kit of claim 17, wherein the therapeutic antibody or antigen-binding fragment thereof specifically binds to an antigen specifically expressed by tumor cells or virally-infected cells. 54. The composition of claim 1, wherein the inhibitory receptor expressed on the surface of an NK cell is selected from the group consisting of KIR2DL1, KIR2DL2/3, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, NKG2A, NKG2C NKG2E and LILRB5. 55. The kit of claim 17, wherein the inhibitory receptor expressed on the surface of an NK cell is selected from the group consisting of KIR2DL1, KIR2DL2/3, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, NKG2A, NKG2C NKG2E and LILRB5. 56. The composition of claim 1, wherein said NK cell-potentiating compound enhances the ability of said therapeutic antibody to deplete said target cells by ADCC by at least 100%. 57. The composition of claim 1, wherein said NK cell-potentiating compound enhances the ability of said therapeutic antibody to deplete said target cells by ADCC by at least 200%. 58. The composition of claim 1, wherein said NK cell-potentiating compound enhances the ability of said therapeutic antibody to deplete said target cells by ADCC by at least 300%.

Details for Patent 9,090,876

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2023-07-24
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2023-07-24
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2023-07-24